Fact.MR – A Market Research and Competitive Intelligence Provider: As per the newly released data by Fact.MR, the global sterile compounding pharmacies market reached US$ 5.07 Bn in 2020 and is projected to surpass US$ 8.9 Bn by the end of 2031.
Seven out of Every Ten Sterile Compounding Medicines Sales to come from the U.S.
Fact.MR’s latest report on sterile compounding pharmacies market provides a meticulous analysis of prevailing dynamics, ongoing developments, and trending business strategies. It studies in detail various growth drivers, restraints, challenges and opportunities affecting the demand across leading segments in terms of product, therapeutic area, and end user.
Fact.MR – A Market Research and Competitive Intelligence Provider: As per the newly released data by Fact.MR, the global sterile compounding pharmacies market reached US$ 5.07 Bn in 2020 and is projected to surpass US$ 8.9 Bn by the end of 2031.
With rising demand for custom compounded formulations and increasing pharmaceutical spending, the overall market is slated to expand at 7.2% CAGR between 2021 and 2031.
Compounding pharmacies use a doctor’s prescription to create customized medication. These customized medications offer therapeutic alternatives for patients with unique medical needs that cannot be met by the U.S. Food and Drug Administration (FDA) approved drugs.
Factors such as high risk of infection through drugs administered using injection through an IV or directly into the eyes are increasing the demand for sterile compounding. It involves creating a medication in an environment free from contaminating agents such as viruses and bacteria.
These drugs need to be carefully prepared in a separate sterile room to minimize the risk of contamination. Hence, adoption of sterile compounding is expected to surge over the forecast period.
Shortage of various types of drugs due to quality and manufacturing issues will boost the demand for sterile compounding pharmacies.
Furthermore, manufacturers are integrating latest technologies such as automation, in the compounding procedures to minimize human involvement. This will aid the production of high quality compounding products with greater efficiency.
Request a report sample to gain compressive insights at
https://www.factmr.com/connectus/sample?flag=S&rep_id=7061
According to Fact.MR, injectable are among highly preferred sterile compounding products due to their faster mode of action. Meanwhile, sales of ocular compounded ophthalmic medications are projected to account for the second largest share of 15.5% by 2031 in this market. This is attributable to the increasing prevalence of ophthalmic disorders across the world.
Regionally, North America will continue to dominate the sterile compounding pharmacies market with the U.S. accounting for 72% market share through 2031. Growing awareness among people, adoption of automation in compounding procedures, strong presence of leading market players, and increasing spending on medicines are some of the factors boosting the market in the U.S.
“Minimizing risk in sterile compounding process is crucial for maintaining the quality of the product. As a result, sterile compounding pharmacies are shifting towards automation. Adoption of robotics and other latest technologies ensure safety while reducing human related mistakes in the entire process. This is expected to create growth opportunities for the market.” says the Fact.MR analyst.
Key Takeaways from Sterile Compounding Pharmacies Market Survey
- With increasing spending on medicine and highly advanced healthcare infrastructure, the U.S. is expected to account for around 77.2% share in 2021.
- Canada’s sterile compounding pharmacies market is poised to exhibit a CAGR of 8.9% between 2021 and 2031.
- Owing to the growing demand for sterile compounding formulations along with presence of leading players, the U.K. is set to account for around 34% share of the Europe market.
- Australia and New Zealand, collectively, accounted for around 54% market share of Asia Pacific in 2031.
- Based on product, ocular segment is projected to account for 15.5% market share during the forecast period.
- In terms of therapeutic area, hormone replacement therapy segment is poised to expand at 5% CAGR between 2021 and 2031.
Key Drivers
- Increasing preference for personalized medicines spurs the growth of sterile compounding pharmacies market.
- Rising geriatric population, high prevalence of diseases, and shortage of essential medicines are supporting the growth of the market.
- Adoption of robotic automation for increasing the efficiency and quality of drug compounding is reshaping the sterile compounding pharmacies market.
Key Restraints
- Shortage of skilled lab technicians and pharmacists is restraining the market growth.
- High cost associated with maintenance of sterile environment also limits the market growth.
To gain in-depth insights on Sterile Compounding Pharmacies Market, request methodology at
https://www.factmr.com/connectus/sample?flag=RM&rep_id=7061
Competitive Landscape
Key companies operating in the sterile compounding pharmacies market are deploying necessary resources to meet the new U.S. Pharmacopeia (USP) standards for enhanced patient and staff safety.
They have adopted various growth strategies such as mergers, acquisitions, new product launches, and collaborations to expand their global footprint. For instance,
- In September 2019, QuVa Pharma, Inc. announced immediate significant capacity increase for compounded sterile injectable preparation.
- In November 2020, Fagron Sterile Services US expanded its product portfolio by introducing a new platform with multiple presentations available- Intravenous (IV) Bags. The new platform launches with multiple presentations of fentaNYL, HYDROmorphone and midazolam.
- In February 2019, Fagron North America, a leading supplier of compounded medications to hospital pharmacies and patients, announced the opening of one of the largest 503B human drug outsourcing facilities in the U.S. in November, which will utilize automation for sterile compounding process.
Some of the prominent players operating in the sterile compounding pharmacies market profiled by Fact.MR are:
- Fagron
- Fresenius Kabi AG
- PharMEDium Services, LLC
- Institutional Pharmacy Solutions
- Cantrell Drug Company
- Lorraine’s Pharmacy
- B. Braun Melsungen AG Company
More Insights on the Sterile Compounding Pharmacies Sales Outlook
Fact.MR provides an unbiased analysis of sterile compounding pharmacies market, presenting historical demand data (2016-2020) and forecast statistics for the period from 2021-2031. The study divulges compelling insights on the global demand for sterile compounding pharmacies with a detailed segmentation on the basis of:
Product
- Injectables
- Nasal
- Ocular
- Otic
Therapeutic Area
- Hormone Replacement Therapy
- Pain Management
- Dermatology
- Oncology
- Hematology
- Dental
- Others
End User
- Adults
- Pediatrics
- Geriatrics
- Veterinary
Key Questions Covered in the Sterile Compounding Pharmacies Market Outlook Report
- The report offers insight into sterile compounding pharmacies demand outlook for 2021-2031
- The market study also highlights projected sales growth for sterile compounding pharmacies market between 2021 and 2031
- Sterile compounding pharmacies market survey identifies key growth drivers, restraints, and other forces impacting prevailing trends and evaluation of current market size and forecast and technological advancements within the industry
- Sterile compounding pharmacies market share analysis of the key companies within the industry and coverage of strategies such as mergers & acquisitions, joint ventures, collaborations or partnerships, and others
Explore Fact.MR’s Coverage on the Healthcare Domain –
Generic Injectables Market- Governments around the world are promoting the distribution and production of generic drugs in order to make them more accessible to a larger population, particularly in developing countries’ rural areas. Generic drug development is a low-cost process. This is due to the fact that they are not required to conduct clinical trials or toxicology investigations. The generic injectables market is expected to be boosted by the expiration of patents on blockbuster injectable drugs, research and development of large molecule generic injectables, and a robust pipeline of pharmaceuticals.
Intranasal migraine drugs Market- The sickness problem is becoming more prevalent among adults, increasing the need for intranasal anti-infection agent treatment. The increased prevalence of the disease, rising acceptance of novel medications, and the introduction of treatments based on calcitonin quality related peptide are some of the factors driving the industry’s growth (CGRP). Nonetheless, the outcomes associated with these drugs may stymie market growth. Agony-relieving drugs continue to be the most profitable segment of the global intranasal migraine drugs market.
Ocular Drug Delivery Technology Market- The ocular drug delivery market is undergoing extensive research and development. Shortages in such medications’ bioavailability are a major growth driver. Micellar formulations and derivative active pharmaceutical ingredients have proved to offer a lot of room for advancement, according to studies. The global ocular drug delivery technology market is expected to grow at a healthy rate based on these factors. The high acceptance of intraocular implants, owing to their targeted action and long-term performance, has enhanced the technology’s growth prospects.
About Fact.MR
Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. Spanning a wide range – from automotive & industry 4.0 to healthcare, technology to even the most niche categories. 80% of Fortune 1000’s trust us in critical decision making.
MarketNgage is powered by Fact.MR – our Unified Intelligence Engine, a revolutionary Market Research Subscription platform with a flexible pricing to suit your needs.
You can access all our healthcare research reports by signing up with MarketNgage’s Market Research Subscription with FREE credits. MarketNgage is powered by Fact.MR – A Fully integrated research solution for seamless single-window access Widest coverage on emerging markets, nascent products, and disruptive technologies.
Contact:
Mahendra Singh
US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E: sales@factmr.com
Source: Fact.MR